Abstract
Purpose Recently, Eyetronix Flicker Glass (EFG) was introduced as a novel treatment for amblyopia. We conducted a randomized clinical trial to compare the efficacy of the therapies using the Eyetronix Flicker Glass and standard adhesive patches.
Methods We tested 31 children (aged 4-13 years) with anisometropic amblyopia. They were assigned into one of the two treatment groups and were treated for 12 weeks. The first group was treated with the Eyetronix Flicker Glass for one hour per day (Flicker Group), and the latter with standard patches (Patching Group) for two hours per day. We considered best-corrected visual acuity (BVCA) of the amblyopic eye after 12 weeks of treatment as the primary outcome. Secondary outcomes were BVCA of the amblyopic at other timepoints of measurement (before the treatment, 3 and 6 weeks) as well as contrast sensitivity of the amblyopic eye, stereopsis and fusion range at all timepoints.
Results Visual acuity in the amblyopic eye was significantly improved in both treatment groups at week 12 relative to baseline. The magnitude of improvement was similar. Contrast sensitivity of the amblyopic eye at 3, 6 and 12 cpd was large but not so at 18 cpd for both groups. Stereopsis did not improvement in both groups. However, fusion range significantly improved in the Flicker Group at week 12 relative to baseline.
Conclusion After 12 weeks, EFG therapy improves amblyopic eye’s visual acuity, its contrast sensitivity and fusion range of the patients. EFG therapy improves both monocular and binocular functions.
Clinical trial registry number ChiCTR2000034436 from the Chinese Clinical Trial Registry
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2000034436
Funding Statement
This research was supported by National Natural Science Foundation of China (Grant Nos. 31970975 and 81500754) and the Wenzhou Medical University grant (QTJ16005) to JWZ and Canadian institute of Health Research graduate award to SHM.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research protocol and the informed consent forms were reviewed and approved by the ethics committee of the Affiliated Eye hospital at Wenzhou Medical University (2016-18-Q-11).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
Data supporting the findings of this study are available from the corresponding author upon request.
